Ritesh Rathore, MD is an Associate Professor of Medicine at Boston University School of Medicine. He specializes in Hematology Oncology. His research interests include gastrointestinal cancer, biologic therapy, head/neck/thoracic cancers and clinical trials. He speaks four languages: English, Hindi, Bengali and Gujarati.
- Roger Williams Medical Center
- University College of Medical Sciences, MBBS
- Published on 11/23/2017
Reha J, Mukkamalla SKR, Rathore R, Somasundar PS. Adequate lymph node evaluation in the elderly is associated with improved survival in patients with stage I-III colon cancer: A validation study using the National Cancer Data Base. Eur J Surg Oncol. 2018 Jan; 44(1):148-156. PMID: 29198492.
- Published on 6/21/2016
Junghans RP, Ma Q, Rathore R, Gomes EM, Bais AJ, Lo AS, Abedi M, Davies RA, Cabral HJ, Al-Homsi AS, Cohen SI. Phase I Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response. Prostate. 2016 Oct; 76(14):1257-70. PMID: 27324746.
- Published on 2/23/2015
Vaishampayan U, Thakur A, Rathore R, Kouttab N, Lum LG. Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients. Prostate Cancer. 2015; 2015:285193. PMID: 25802762.
- Published on 2/16/2015
Lum LG, Thakur A, Al-Kadhimi Z, Colvin GA, Cummings FJ, Legare RD, Dizon DS, Kouttab N, Maizel A, Colaiace W, Liu Q, Rathore R. Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial. Clin Cancer Res. 2015 May 15; 21(10):2305-14. PMID: 25688159.
- Published on 4/1/2014
Birnbaum A, Dipetrillo T, Rathore R, Merriam P, Wanebo H, Thomas A, Puthawala Y, Joyce D, Luppe D, Khurshid H, Follett N, Sio TT, Safran H. Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a survival analysis of a Brown University Oncology Group phase II study. Am J Clin Oncol. 2014 Apr; 37(2):162-6. PMID: 23275269.
- Published on 9/23/2013
Lum LG, Thakur A, Pray C, Kouttab N, Abedi M, Deol A, Colaiace WM, Rathore R. Multiple infusions of CD20-targeted T cells and low-dose IL-2 after SCT for high-risk non-Hodgkin's lymphoma: a pilot study. Bone Marrow Transplant. 2014 Jan; 49(1):73-9. PMID: 24056738.
- Published on 2/1/2012
Ready NE, Rathore R, Johnson TT, Nadeem A, Chougule P, Ruhl C, Radie-Keane K, Theall K, Wanebo HJ, Marcello J, Kennedy T. Weekly paclitaxel and carboplatin induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck. Am J Clin Oncol. 2012 Feb; 35(1):6-12. PMID: 21293244.
- Published on 5/7/2011
Wanebo HJ, Rathore R, Chougule P, DiSiena MR, Koness RJ, McRae RG, Nigri PT, Radie-Keane K, Ready N. Selective organ preservation in operable locally advanced head and neck squamous cell carcinomas guided by primary site restaging biopsy: long-term results of two sequential brown university oncology group chemoradiotherapy studies. Ann Surg Oncol. 2011 Nov; 18(12):3479-85. PMID: 21553142.
- Published on 4/1/2010
Birnbaum A, Dipetrillo T, Rathore R, Anderson E, Wanebo H, Puthwala Y, Joyce D, Safran H, Henderson D, Kennedy T, Ready N, Sio TT. Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a toxicity analysis. Am J Clin Oncol. 2010 Apr; 33(2):144-7. PMID: 19786848.
- Published on 2/4/2010
Rathore R, Birnbaum A, Rathore B, DiPetrillo T, Kennedy T, Ready N. Carboplatin with weekly docetaxel and ifosfamide in advanced head and neck cancers: a phase I Brown University Oncology Group dose escalation study (HN-93). Cancer Chemother Pharmacol. 2010 Nov; 66(6):1013-7. PMID: 20130878.
View 15 more publications: View full profile at BUMC